Boston Scientific (BSX): Alphinity Investment Management Pty Ltd opened a new position $253M
Alphinity Investment Management Pty Ltd opened a new position in Boston Scientific, per its Q4 2025 13F.
- 2.65M
- Shares reported
- 2.6%
- Disclosed portfolio weight
- $253M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- Jan 28, 2026
What stands out in this filing
- A new position in Q4 2025: 2,652,522 shares, none in the manager's Q3 2025 filing.
- Reported at $253M, 2.56% of the portfolio value in this 13F filing.
- 14 other tracked managers reported the same kind of change for Q4 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 18, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Dec 1, 2025InsiderOfficer sold ~$1.76M of BSX shares in the open market
- Dec 16, 2025Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
- Dec 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Dec 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Dec 29, 2025CongressDisclosed purchase of BSX — reported range $15,001 - $50,000
- Jan 14, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
What came next
- Jan 30, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
- Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$15.0M)
- Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 10, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Feb 12, 2026Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
- Feb 18, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of…”
- Feb 26, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
- Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: In re: Boston Scientific Corporation Securities Litigation
- Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: Troike v. Boston Scientific Corporation
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 22, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- Apr 30, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
- May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 5.1%
- May 12, 2026FDARecall: Orca Single Use Air/Water and Suction Valves, Material Number (UPN) SUV-617-50; The Orca Air/Water Valve is intended to be used to control the air/water functi…
- May 15, 2026FDAFDA device clearance: TruSelect 2.6 Microcatheter
- May 18, 2026FDAFDA device clearance: MOSES Raydar
- May 19, 2026Insider · First insider buy since Dec 2024Director purchased ~$125K of BSX shares in the open market
- May 20, 2026Insider · 3 peopleInsiders: 3 purchases (~$429K)
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Boston Scientific
For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.
How this filing works
Explore the data
Common questions
What does this filing report about Boston Scientific (BSX) stock?
Alphinity Investment Management Pty Ltd opened a new position in Boston Scientific, per its Q4 2025 13F. 2.65M shares reported, 2.6% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2025. Filed: Jan 28, 2026.
What stands out in this filing?
A new position in Q4 2025: 2,652,522 shares, none in the manager's Q3 2025 filing. Reported at $253M, 2.56% of the portfolio value in this 13F filing. 14 other tracked managers reported the same kind of change for Q4 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Boston Scientific recently?
For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the BSX page.
Does this mean BSX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Boston Scientific
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
Everything OQRO holds on this company is on its BSX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
